Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.62 |
| ▸ | FAAH | O00519 | 5/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.60 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.60 |
| ▸ | PTGS1 | P23219 | 7/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17192626 | 0.92 | MGLL (0.68) | MGLLFAAHNPSR1ALDH1A1LMNA | |
| SCHEMBL23181692 | 0.92 | MGLL (0.68) | MGLLFAAHNPSR1ALDH1A1LMNA | |
| SCHEMBL12599169 | 0.86 | MGLL (0.54) | MGLLFAAHNPSR1ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL28493448 | 0.84 | MGLL (0.52) | MGLLFAAHNPSR1ALDH1A1LMNA | |
| SCHEMBL5146869 | 0.82 | MGLL (0.68) | MGLLFAAHNPSR1ALDH1A1LMNA | |
| SCHEMBL1972894 | 0.79 | MGLL (0.46) | MGLLFAAHNPSR1ALDH1A1LMNA | |
| SCHEMBL9999884 | 0.79 | PTGS1 (0.47) | MGLLFAAHNPSR1ALDH1A1LMNA | |
| SCHEMBL1324812 | 0.78 | MGLL (0.62) | MGLLFAAHNPSR1ALDH1A1LMNA | |
| Dimethylamine SCHEMBL181458 | 0.78 | MGLL (0.73) | MGLLFAAHNPSR1ALDH1A1LMNA | |
| SCHEMBL155748 | 0.78 | MGLL (1.00) | MGLLFAAHNPSR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210108201-A1 | FN3 Domain-siRNA Conjugates and Uses Thereof | Aro Biotherapeutics Company | 2021-04-15 | — | — | US | disclosed |
| WO-2021048469-A1 | POLYMER AND COMPOSITION FROM RENEWABLE SOURCE | ÅBO AKADEMI UNIVERSITY (FI) | 2021-03-18 | — | — | WO | disclosed |
| US-20150284416-A1 | NOVEL LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | SUZHOU M-CONJ BIOTECH CO., LTD (CN) | 2015-10-08 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | MGLL 3415/4885FAAH 3699/4885NPSR1 3021/4885 |
| US-20150284416-A1 | NOVEL LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES | EPCAM, CD2BP2, CD44 | MGLL 4220/4885FAAH 2729/4885NPSR1 1305/4885 |
| US-20210108201-A1 | FN3 Domain-siRNA Conjugates and Uses Thereof | FN1, ITGB3, FNIP1 | MGLL 4522/4885FAAH 4348/4885NPSR1 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.